https://www.selleckchem.com/pr....oducts/anlotinib-al3
The women with a BRCA mutation were significantly more likely to elect for bilateral mastectomy than the women without a BRCA mutation (p 0.0001). Of the BRCA-positive patients, 95.7% reported that they used their genetic test result to make a surgical decision. The women provided with RGT at the time of breast cancer diagnosis use the genetic information to make treatment decisions, and the majority of those identified with a BRCA mutation elect for a bilateral mastectomy. The women provided with RGT at the time of breast
Like
Comment
Share
